Related Experiment Video

Updated: Oct 17, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.4K

Efficacy of moisturizers in paediatric atopic dermatitis: A systematic review and meta-analysis of randomised

Chawan Kritsanaviparkporn1, Phoomphut Sangaphunchai1, Arucha Treesirichod1

  • 1Department of Paediatrics, Faculty of Medicine, Srinakharinwirot University, Ongkharak, Nakhonnayok, Thailand.

Indian Journal of Dermatology, Venereology and Leprology
|October 8, 2021
PubMed

Insights

Topical moisturizers significantly benefit young patients with atopic dermatitis by extending time to flare and reducing relapse risk. Further research is needed to fully establish efficacy, but current evidence supports their use.

Area of Science:

  • Dermatology
  • Pediatrics
  • Evidence-based Medicine

Background:

  • Atopic dermatitis (AD) is a common chronic inflammatory skin condition in children.
  • Topical moisturizers are a cornerstone of AD management, aiming to improve skin barrier function and hydration.

Purpose of the Study:

  • To systematically review and meta-analyze the efficacy of topical moisturizers in pediatric patients (≤15 years) with atopic dermatitis.
  • To identify knowledge gaps concerning moisturizer effectiveness in this population.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs).
  • Included trials compared topical moisturizer use versus no moisturizer in children with AD.
  • Certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework.

Main Results:

  • Six trials involving 436 patients (intervention) and 312 (control) were analyzed.
  • Moisturizer use extended time to flare by 13.52 days and reduced relapse risk, particularly in the first month.
  • Patients using moisturizers were more likely to achieve 3-6 months remission; disease severity and quality of life showed minimal improvement.

Conclusions:

  • Topical moisturizers demonstrate clear benefits for young patients with atopic dermatitis.
  • The current evidence supports moisturizer use, but highlights the need for more robust, standardized RCTs to refine efficacy estimates.
Abstract

Keywords:
Emollientatopic dermatitischildrenmoisturizer

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

9.8K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
36
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
34
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
35
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
31
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
43